The lancet oncology
-
The lancet oncology · Dec 2022
Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study.
The EUROCARE-5 study revealed disparities in childhood cancer survival among European countries, giving rise to important initiatives across Europe to reduce the gap. Extending its representativeness through increased coverage of eastern European countries, the EUROCARE-6 study aimed to update survival progress across countries and years of diagnosis and provide new analytical perspectives on estimates of long-term survival and the cured fraction of patients with childhood cancer. ⋯ European Commission.
-
The lancet oncology · Dec 2022
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE.
Shortages and unequal access to anticancer medicines for children and adolescents are a reality in Europe. The aim of the European Society for Paediatric Oncology (SIOPE) Essential Anticancer Medicines Project was to provide a list of anticancer medicines that are considered essential in the treatment of paediatric cancers to help ensure their continuous access to all children and adolescents with cancer across Europe. ⋯ None.